Investigational drug · Phase 3
Setrusumab
Also called: BPS804, UX143
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Osteogenesis Imperfecta.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
10
Any phase or sponsor naming "Setrusumab"
First trial start
2022
Feb 21, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Setrusumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Osteogenesis Imperfecta
Largest trials
Live from ClinicalTrials.gov: studies naming "Setrusumab" as an intervention, largest first.
- Setrusumab vs Placebo for Osteogenesis ImperfectaPivotal-lookingActive, not recruiting
Ultragenyx Pharmaceutical IncIndustry
NCT05125809 · 183 participants · Start Feb 21, 2022 · Primary completion Oct 20, 2025
Drug: Setrusumab · For: Osteogenesis Imperfecta
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 43 sites in all
- A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804Pivotal-lookingCompleted
Ultragenyx Pharmaceutical IncIndustry
NCT03118570 · 112 participants · Start Sep 11, 2017 · Primary completion Oct 1, 2019
Drug: setrusumab; zoledronic acid (optional) · For: Osteogenesis Imperfecta, Type I; Osteogenesis Imperfecta Type III; Osteogenesis Imperfecta Type IV
Sites: Birmingham, Alabama; Jacksonville, Florida; Baltimore, Maryland · 25 sites in all
- Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaPivotal-lookingActive, not recruiting
Ultragenyx Pharmaceutical IncIndustry
NCT05768854 · 69 participants · Start Jun 14, 2023 · Primary completion Oct 23, 2025
Drug: Bisphosphonate; Setrusumab · For: Osteogenesis Imperfecta
Sites: Phoenix, Arizona; Los Angeles, California; Aurora, Colorado · 20 sites in all
Ultragenyx Pharmaceutical IncIndustry
NCT01406548 · 44 participants · Start Jul 2011 · Primary completion Oct 2013
Drug: BPS804 20mg/Kg; Placebo to 20mg/Kg BPS804 · For: Osteopenia; Osteoporosis
Sites: Anaheim, California; Miami, Florida; Berlin, New Jersey · 5 sites in all
Ultragenyx Pharmaceutical IncIndustry
NCT01417091 · 10 participants · Start Jun 2011 · Primary completion Dec 2012
Drug: BPS804 · For: Osteogenesis Imperfecta
Sites: Anaheim, California; Miramar, Florida; Brussels, Belgium · 6 sites in all
Ultragenyx Pharmaceutical IncIndustry
NCT01406977 · 8 participants · Start Jul 2011 · Primary completion Sep 2012
Drug: BPS804 · For: Hypophosphatasia
Sites: Würzburg, Germany
- Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaPivotal-lookingActive, not recruiting
Ultragenyx Pharmaceutical IncIndustry
NCT06636071 · 6 participants · Start Oct 25, 2024 · Primary completion Jan 2027
Drug: setrusumab · For: Osteogenesis Imperfecta
Sites: Osaka, Japan; Tokyo, Japan · 3 sites in all
- Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis ImperfectaTerminated
Ultragenyx Pharmaceutical IncIndustry
NCT05312697 · 2 participants · Start Apr 28, 2022 · Primary completion Jul 7, 2022
Drug: Setrusumab · For: Osteogenesis Imperfecta
Sites: Albuquerque, New Mexico
Ultragenyx Pharmaceutical IncIndustry
NCT03216486 · 0 participants · Start Oct 31, 2017 · Primary completion Nov 1, 2018
Drug: BPS804 · For: Osteogenesis Imperfecta
Sites: Albuquerque, New Mexico; Houston, Texas
- Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney DiseaseWithdrawn
Ultragenyx Pharmaceutical IncIndustry
NCT01806610 · 0 participants · Start Aug 2013 · Primary completion Apr 2014
Drug: BPS804; Placebo · For: Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Newest research
PubMed records naming it or its code names, newest first.
- Pathogenesis and precision management of osteogenesis imperfecta: from genetic mechanisms to novel therapies.
Wang XQ, Zhang C, Li X, et al. · World J Pediatr 2026
- Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis.
Li C, Dai Z, Tang WC, et al. · J Med Internet Res 2026
- What's New in Osteogenesis Imperfecta.
Wallace M, Menapace B, Herrero C, et al. · J Pediatr Soc North Am 2026
- Correction to: Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.
· J Bone Miner Res 2025
- Non-invasive quantification of bone (re)modeling dynamics in adults with osteogenesis imperfecta treated with setrusumab using timelapse high-resolution peripheral-quantitative computed tomography.
Hosseinitabatabaei S, Vitienes I, Rummler M, et al. · J Bone Miner Res 2025
- Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?
Chapurlat R · Expert Opin Investig Drugs 2025
Also in development for Osteogenesis Imperfecta
- BisphosphonatePhase 32 trials
Ultragenyx Pharmaceutical Inc · Osteogenesis Imperfecta
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.